Therapy of Hodgkin lymphoma in Russia during the COVID-19 pandemic

Cover Page
  • Authors: Poddubnaya I.V.1, Baryakh E.A.2, Vorobyev V.I.3, Demina E.A.4, Zhukov N.V.5, Kaplanov K.D.6,7, Konstantinova T.S.8, Motorin D.V.9, Ptushkin V.V.10, Sarzhevsky V.O.11, Tumyan G.S.12,13
  • Affiliations:
    1. Russian Medical Academy of Continuous Professional Education
    2. City Clinical Hospital №52
    3. Botkin Moscow City Clinical Hospital
    4. FSBI National Medical and Surgical Center named after N.I. Pirogova »Ministry of Health of Russia
    5. Federal State Budgetary Institution National Medical Research Center for Pediatric Hematology, Oncology and Immunology Dmitry Rogachev"
    6. GBUZ "Volgograd Regional Clinical Oncology Center"
    7. FSBEI HE "Volgograd State Medical University" of the Ministry of Health of Russia
    8. Sverdlovsk Regional Clinical Hospital No. 1
    9. National Medical Research Center named after V.A. Almazov» Ministry of Health of Russia
    10. City Clinical Hospital named after S.P. Botkin
    11. Federal State Autonomous Educational Institution of Higher Education “Russian National Research Medical University named after N.I. Pirogov» Ministry of Health of Russia
    12. FSBEI DPO “Russian Medical Academy of Continuing Professional Education” of the Ministry of Health of Russia
    13. FSBI “National Medical Research Center of Oncology named after N.N. Blokhina» Ministry of Health of Russia
  • Issue: Vol 22, No 2 (2020)
  • Pages: 52-55
  • Section: Conference Proceedings
  • URL: https://modernonco.orscience.ru/1815-1434/article/view/34878
  • DOI: https://doi.org/10.26442/18151434.2020.2.200206
  • Cite item

Abstract


Relevance. COVID-19 pandemic currently has a significant negative impact on the treatment of patients with oncological pathology, including patients with classic Hodgkin lymphoma. Generalized data on publications on the impact of concomitant pathology on the severity of infection show a significant increase in the risk of death from infection in male patients, aged >60 years, with the presence of ≥3 concomitant diseases, among which particularly negative role is played by diseases of the cardiovascular system, diabetes, oncology, chronic lung disease, immunodeficiency conditions. Particularly dangerous is the development of COVID-19 infection in an interval of less than 14 days from the course of antitumor therapy. At the same time, patients with Hodgkin lymphoma require immediate treatment, often associated with toxic, immunosuppressive therapy, frequent visits to the clinic, hospitalizations. International communities have not yet developed clear guidelines for the management of patients with Hodgkin’s lymphoma. Taking into account the understanding that the circulation of coronoviral infection will continue in the population, the Advisory board on the Problems of Hodgkin Lymphoma Therapy in the COVID-19 Pandemic is highly relevant.

Aim. To change and adapt current treatment approaches in the current epidemiological environment.

Results. The main directions of the impact of the COVID-19 pandemic on the treatment of patients with cancer pathology, including patients with classical Hodgkin lymphoma, were determined, key problems in the treatment of LC during the COVID-19 pandemic were identified, and measures aimed at reducing the risk for patients were developed. Existing approaches to first-line, relapse/refracturing cHL therapy, including salvage therapy, and auto/allo SCT during the COVID-19 pandemic, have been adapted.


Full Text

Restricted Access

About the authors

Irina V. Poddubnaya

Russian Medical Academy of Continuous Professional Education

Author for correspondence.
Email: ivprectorat@inbox.ru
ORCID iD: 0000-0002-0995-1801

Russian Federation, Moscow

D. Sci. (Med.), Prof., Acad. RAS

Elena A. Baryakh

City Clinical Hospital №52

Email: ebaryakh@gmail.com
ORCID iD: 0000-0001-6880-9269

Russian Federation, Moscow

Cand. Sci. (Med.)

Vladimir I. Vorobyev

Botkin Moscow City Clinical Hospital

Email: morela@mail.ru

Russian Federation, Moscow

Ph.D., hematologist of hematology department No. 6

E. A. Demina

FSBI National Medical and Surgical Center named after N.I. Pirogova »Ministry of Health of Russia

Email: or@hpmp.ru

Russian Federation, Moscow

Dr. med. sciences, prof., prof. cafe Hematology and Cell Therapy Institute for Advanced Medical Studies, Member of the Board of the Russian Society of Oncohematologists

Nikolay V. Zhukov

Federal State Budgetary Institution National Medical Research Center for Pediatric Hematology, Oncology and Immunology Dmitry Rogachev"

Email: or@hpmp.ru

Russian Federation, Moscow

Dr. med. sciences, head. Dep. Interdisciplinary Oncology

K. D. Kaplanov

GBUZ "Volgograd Regional Clinical Oncology Center"; FSBEI HE "Volgograd State Medical University" of the Ministry of Health of Russia

Email: or@hpmp.ru

Russian Federation, Volgograd

Cand. med. sciences, head. Department of Hematology, Assistant oncology with a course of oncology and hematology FUV, member of the Russian Society of Oncohematologists and the National Hematology Society

T. S. Konstantinova

Sverdlovsk Regional Clinical Hospital No. 1

Email: or@hpmp.ru

Russian Federation, Yekaterinburg

Cand. med. sciences, head. Department of Hematology, hematologist of the highest category, chapters. Freelance hematologist of the Ural Federal District and the Ministry of Health of the Sverdlovsk Region

Dmitry V. Motorin

National Medical Research Center named after V.A. Almazov» Ministry of Health of Russia

Email: or@hpmp.ru

Russian Federation, St. Petersburg

Cand. Med. Sciences, Department of Chemotherapy of Oncohematological Diseases and Bone Marrow Transplantation No. 2

V. V. Ptushkin

City Clinical Hospital named after S.P. Botkin

Email: or@hpmp.ru

Russian Federation, Moscow

Dr. med. sciences, prof., deputy chapters. hematology doctor, chapters. Freelance specialist-hematologist of the Moscow Department of Health, member of the National Hematology Society and the Russian Society of Oncohematologists

Vladislav O. Sarzhevsky

Federal State Autonomous Educational Institution of Higher Education “Russian National Research Medical University named after N.I. Pirogov» Ministry of Health of Russia

Email: or@hpmp.ru

Russian Federation, Moscow

Dr. med. sciences, prof. cafe Hematology and Cell Therapy Institute for Advanced Medical Studies

G. S. Tumyan

FSBEI DPO “Russian Medical Academy of Continuing Professional Education” of the Ministry of Health of Russia; FSBI “National Medical Research Center of Oncology named after N.N. Blokhina» Ministry of Health of Russia

Email: or@hpmp.ru

Russian Federation, Moscow

Dr. med. sciences, prof., prof. cafe oncology and palliative medicine, Vedas. scientific al. Hemoblastosis chemotherapy department, member of the board of the Russian Society of Oncohematologists

References

  1. https://www.worldometers.info/coronavirus/
  2. https://www.cdc.gov/coronavirus/2019-ncov/
  3. https://www.hematology.org/covid-19/covid-19-and-hodgkin-lymphoma
  4. https://www.esmo.org/guidelines/cancer-patient-management-during-the-covid-19-pandemic/haematological-malignancies-hodgkin-lymphoma-in-the-covid-19-era/
  5. Liang W et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncology 2020; 21 (3): 335–7. doi: 10.1016/S1470-2045(20)30096-6
  6. Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. JAMA 2020; 32 3(18): 1775–6. doi: 10.1001/jama.2020.4683
  7. Lambertini M, Toss A, Passaro A et al. Cancer care during the spread of coronavirus disease 2019 (COVID-19) in Italy: young oncologists’perspective. ESMO Open 2020; 5: e000759. doi: 10.1136/esmoopen-2020-000759
  8. Hanna TP, Evans GA, Booth CM et al. Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemic. Nat Rev Clin Oncol 2020; 17: 268–70.
  9. Bersanelli M. Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors. Immunotherapy 2020; 0(0): imt-2020-0067. doi: 10.2217/imt-2020-0067
  10. https://clinicaltrials.gov/ct2/show/NCT03474133?term=basalt&draw=2&rank=1

Statistics

Views

Abstract - 103

PDF (Russian) - 2

Cited-By


PlumX

Dimensions

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies